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Introduction
Because fibromyalgia syndrome and chronic fatigue
syndrome (CFS) share symptoms, it may be asked whether
fibromyalgia and CFS are two entities or only two
syndromes of a spectrum of similar disorders of common
etiology and pathogenesis. Fibromyalgia and CFS are
clinically overlapping, stress-related syndromes that
primarily affect women [1,2]. Fibromyalgia is characterized
by widespread chronic pain affecting the musculoskeletal
system, with defined tender points apparent on
examination [3]. It is also associated with sleep distur-
bance and fatigue, suggesting overlap with CFS. In
addition, patients with CFS often complain of
musculoskeletal discomfort accompanied by tender points.
Neuroendocrine abnormalities have been observed in both
disorders, including dysregulation of the hypothalamic–
pituitary–adrenal (HPA) and hypothalamic–pituitary–gonadal
(HPG) axes [4–6].
Endocrine regulation is considerably impaired in both
conditions, with many hormonal mechanisms altered.
Therefore, neuromediator and hormonal abnormalities may
play an important role in the pathogenesis of fibromyalgia
and CFS [7]. An increasing amount of literature dealing
with endocrine and neuroendocrine data in fibromyalgia
and CFS has been published in the past several years.
BDI = Beck Depression Inventory; CFS = chronic fatigue syndrome; FSH = follicle-stimulating hormone; HPA = hypothalamic–pituitary–adrenal;
HPG = hypothalamic–pituitary–gonadal; LH = luteinizing hormone.
Arthritis Research & Therapy    Vol 6 No 3 Gur et al.
Research article
Cortisol and hypothalamic–pituitary–gonadal axis hormones in
follicular-phase women with fibromyalgia and chronic fatigue
syndrome and effect of depressive symptoms on these hormones
Ali Gur1, Remzi Cevik1, Kemal Nas1, Leyla Colpan2 and Serdar Sarac3
1Department of Physical Medicine and Rehabilitation, School of Medicine, Dicle University, DiyarbakIr, Turkey
2Department of Biochemistry, School of Medicine, Dicle University, DiyarbakIr, Turkey
3Department of Physical Medicine and Rehabilitation, Kartal State Hospital, Istanbul, Turkey
Corresponding author: Ali Gur (e-mail: alig@dicle.edu.tr)
Received: 20 Aug 2003   Revisions requested: 26 Sep 2003   Revisions received: 6 Feb 2004   Accepted: 19 Feb 2004   Published: 15 Mar 2004
Arthritis Res Ther 2004, 6:R232-R238 (DOI 10.1186/ar1163)
© 2004 Gur et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in
all media for any purpose, provided this notice is preserved along with the article's original URL.
Abstract
We investigated abnormalities of the hypothalamic–pituitary–
gonadal axis and cortisol concentrations in women with
fibromyalgia and chronic fatigue syndrome (CFS) who were in
the follicular phase of their menstrual cycle, and whether their
scores for depressive symptoms were related to levels of these
hormones. A total of 176 subjects participated — 46 healthy
volunteers, 68 patients with fibromyalgia, and 62 patients with
CFS. We examined concentrations of follicle-stimulating
hormone, luteinizing hormone (LH), estradiol, progesterone,
prolactin, and cortisol. Depressive symptoms were assessed
using the Beck Depression Inventory (BDI). Cortisol levels
were significantly lower in patients with fibromyalgia or CFS
than in healthy controls (P < 0.05); there were no significant
differences in other hormone levels between the three groups.
Fibromyalgia patients with high BDI scores had significantly
lower cortisol levels than controls (P < 0.05), and so did CFS
patients, regardless of their BDI scores (P < 0.05). Among
patients without depressive symptoms, cortisol levels were
lower in CFS than in fibromyalgia (P < 0.05). Our study
suggests that in spite of low morning cortisol concentrations,
the only abnormalities in hypothalamic–pituitary–gonadal axis
hormones among follicular-phase women with fibromyalgia or
CFS are those of LH levels in fibromyalgia patients with a low
BDI score. Depression may lower cortisol and LH levels, or,
alternatively, low morning cortisol may be a biological factor
that contributes to depressive symptoms in fibromyalgia. These
parameters therefore must be taken into account in future
investigations.
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The central stress axis, the HPA axis, seems to play an
important role in fibromyalgia and CFS. Early investiga-
tions postulated hypofunction of the HPA axis in these
conditions, based on the finding of low urinary free
cortisol, and suggested the hypothesis of a common
pathogenesis [8].
Both fibromyalgia and CFS occur more commonly in
women, and there is an increasing incidence of fibro-
myalgia perimenopausally and postmenopausally. This
suggests that alterations in reproductive hormone levels
may be involved in the etiopathology of fibromyalgia and
CFS. Additionally, there have been reports that both
conditions may be due to estrogen deficiency and reflect
underactivity of the HPG axis [9,10]. Stress has been
shown to inhibit gonadotropin-releasing hormone and the
pulsatile secretion of luteinizing hormone. Infusion of
corticotropin-releasing hormone into the cerebral
ventricles leads to inhibition of LH secretion in primates
[11]. Perturbations of HPA axis function have been
described in fibromyalgia and CFS [4,6].
It is increasingly clear that the HPA axis is hyperactive in
fibromyalgia but is typically hypoactive in CFS. One
reason for confusion in endocrinologic research on
fibromyalgia and CFS is the imprecise definition of the two
conditions, their frequent overlap, and confounding
psychiatric conditions that may also affect neuroendocrine
axes [7]. The phase of the patient’s menstrual cycle may
also affect findings. For all these reasons, findings are
strongly dependent on the patients selected for
investigation.
There is no explanation for the higher frequency of fibro-
myalgia in women, which suggests that sex hormones may
have a role in the expression of the disease. Although the
majority of fibromyalgia patients are female, only a few
investigations have paid attention to the changes of sex
hormones in fibromyalgia [12–14]. Riedel and colleagues
[12] investigated female fibromyalgia patients and controls
who were all in the follicular phase of their menstrual
cycle. They found that fibromyalgia patients had
significantly lower estrogen levels despite elevated FSH
levels. Korszun and colleagues [13] and Akkus and
colleagues [14] found no differences from controls in
values of FSH and LH in patients with fibromyalgia.
Interaction between the HPA and HPG axes in stress-
induced amenorrhea suggests that there may be
perturbations of these axes in fibromyalgia and CFS that
contribute to these stress-related diseases. It is important
to detect the role of HPA and HPG axes in the
pathogenesis of fibromyalgia and CFS, to define new
treatment strategies for both. In previous studies of the
conditions, the hormone levels of the HPA and HPG axes
were not evaluated in the same patients. This is the first
study of both the HPG axis and cortisol, which is the most
important hormone of the HPA axis, in follicular-phase
women with fibromyalgia and CFS, and the first to
evaluate the relation between depressive symptoms and
these hormones in the same patients.
We aimed to investigate abnormalities of the HPG axis
and cortisol concentrations in follicular-phase women with
fibromyalgia and CFS, and to find out whether the depres-
sive symptom scores had any relation to these hormones.
Materials and methods
Initially, the 203 subjects studied comprised 46 healthy
volunteers, 68 patients with fibromyalgia only, 62 with
CFS only, and 27 with fibromyalgia and comorbid CFS;
patients were recruited from the Department of Physical
Medicine and Rehabilitation, University Hospital of Dicle,
DiyarbakIr, Turkey. The 27 patients who met the criteria for
both CFS and fibromyalgia were excluded and the study
was therefore completed with 176 subjects. The
diagnosis of fibromyalgia was based on the 1990
American College of Rheumatology criteria [15] and CFS
was diagnosed according to the International CFS
Definition Criteria [16].
The Human Studies Research Committee of the University
of Dicle, DiyarbakIr, approved all procedures, and written
informed consent was obtained from each subject prior to
inclusion in the study. Patients who agreed to enroll in the
trial were examined, and demographic, functional, and
clinical characteristics were documented. All subjects had
a regular menstrual cycle and were fertile.
All patients underwent medical screening that included
physical examination and relevant investigations, including
at least urinalysis; full blood count; measurements of urea,
electrolytes, and erythrocyte sedimentation rate; and tests
of thyroid and liver function. All patients and controls were
evaluated in a structured psychiatric interview to exclude
any additional psychiatric disorder prior to inclusion in the
study. Included subjects had to be free of comorbid
psychiatric disorders as defined in the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition [17].
Depressive symptoms were scored using the Beck
Depression Inventory (BDI) in all patients and controls.
Both patients with CFS and fibromyalgia were divided into
two groups for high or low BDI score according to
whether the BDI score was ≥17 or <17, respectively. They
were free of all medication except stable doses of thyroid
hormone replacement in individuals with treated
hypothyroidism. All prescription medications, included
psychoactive and nonprescription medications, vitamins,
and herbal remedies were tapered and then stopped at
least 2 weeks before the study [5,18]. None of the
patients or controls had frank hypocortisolism on
endocrine assessment. Anyone with a current psychiatricArthritis Research & Therapy    Vol 6 No 3 Gur et al.
R234
history or a past history of depression was excluded from
the study. No patients or controls had received any oral or
intra-articular corticosteroid therapy during the 3 months
preceding the study. All patients and controls were
experiencing normal menstrual cycles and were not taking
any contraceptive pill or any other drugs affecting the
metabolism of sex hormones or of cortisol. Anyone with
abnormal laboratory studies or a current medical problem
other than fibromyalgia or CFS was excluded. The other
exclusion criteria were: active, unresolved, or suspected
disease likely to cause fatigue; alcohol or other substance
abuse within 2 years prior to onset of the chronic fatigue
and any time afterward; and a body mass index ≥45.
Blood samples were collected in the morning
(08.30–10.30 h) after an all-night fast, and plasma was
separated immediately by centrifugation; then sera
obtained were stored at –20°C until hormonal assay. All
hormone values were assayed using Electro Chemil
Luminescence Immunassay (ECLIA) (1010/1020 Elecsys
Systems Immunoassay; Roche Diagnostics, Mannheim,
Germany) method. Serum concentrations of follicle-
stimulating hormone (FSH) (normal values 3.3–11.3 IU/l
for the follicular phase and 1.8–8.2 IU/l for the luteal
phase), luteinizing hormone (LH) (normal values
2.4–12.6 IU/l for the follicular phase and 1.0–11.4 IU/l for
the luteal phase), estradiol (normal values 24.5–195 pg/ml
for the follicular phase and 40–261 pg/ml for luteal
phase), progesterone (normal values 0–1.6 ng/ml for the
follicular phase and 1.1–21 ng/ml for the luteal phase),
prolactin (normal values 3.1–24.6 ng/ml) and cortisol
(normal values 6.2–19.4 µg/dl) were evaluated in all
patients and controls. Patients and controls were studied
during the follicular phase of the menstrual cycle, that is,
within 10 days after the onset of menstruation.
Statistical analyses
Statistical  significance was tested using one-way
analysis of variance and a post hoc Bonferroni test for
multiple group comparisons. All statistical tests were two-
tailed;  P < 0.05 was taken as the level of statistical
significance. Values are expressed as the mean ±
standard deviation.
Results
Baseline characteristics of patients with fibromyalgia or
CFS and of healthy controls are presented in Table 1.
BDI scores in both groups of patients were significantly
higher than those of the control subjects (P < 0.05),
whereas there was no significant difference between the
scores of the two groups of patients (Table 2). There were
no significant differences in FSH, LH, estradiol, prolactin,
or progesterone levels among all the groups, whereas
cortisol levels were significantly lower in both groups of
patients than in healthy controls (P < 0.05). There was no
significant difference in cortisol levels between the two
groups of patients (Table 2).
In this study, high BDI scores (≥17), indicating depression,
were detected in 53% and 66%, respectively, of patients
with fibromyalgia and CFS (Table 3). Among the patients
with fibromyalgia, cortisol levels were significantly lower in
those with high BDI scores than in controls (P < 0.05), but
there was no significant difference between those low BDI
scores and controls. There was no significant difference
between fibromyalgia patients with and those without
depressive symptoms. Cortisol levels in both groups of
CFS patients were significantly lower than in controls
(P < 0.05). Additionally, cortisol levels in CFS patients
without depressive symptoms were lower than those of
fibromyalgia patients without depressive symptoms
(P < 0.05) (Table 3).
LH levels in fibromyalgia patients with low BDI scores
were significantly higher than in those with high BDI
scores and than in controls (P < 0.05). There was no
significant difference between LH levels in fibromyalgia
patients with high BDI scores and controls. Additionally,
among patients with low BDI scores, LH levels were
significantly higher in patients with fibromyalgia than those
with CFS (P < 0.05) (Table 3).
Discussion
In recent years, a novel and paradoxical phenomenon has
emerged from neurobiological studies on the effects of
stress. There is increasing evidence for a relatively
decreased, rather than an increased, cortisol secretion in
individuals who have been exposed to severe stress or
suffer from stress-response-related disorders. The pheno-
menon of hypocortisolism has received growing attention
in the field of stress research, inasmuch as it challenges or
virtually reverses prevailing concepts on the neuro-
endocrinology of stress [19].
Both fibromyalgia and CFS are often viewed as being
stress-response related, and abnormalities of the HPA axis
have been found in both disorders. Stress is also known
to disrupt the HPG axis, and the characteristic repro-
ductive picture of ‘stress’- or exercise-induced amenorrhea
is that of infrequent LH pulses despite follicular-phase
estradiol and progesterone levels [5]. Interestingly, abnor-
malities of the HPA axis reported in other stress-response-
related disorders, such as hypothalamic amenorrhea and
exercise-induced amenorrhea, involve increased baseline
cortisol over 24 hours, whereas previous studies of fibro-
myalgia and CFS found low cortisol [6,20].
In our study, levels of reproductive HPG axis hormones
during the follicular phase showed no significant differ-
ences in women with CFS or fibromyalgia from the values
in controls. These findings are in agreement with those ofKorszun and colleagues [5], who reported data from nine
premenopausal women with fibromyalgia and eight with
CFS. They showed no significant differentiations of
reproductive axis function in either group of patients with
regard to estrogen and progesterone levels and to LH
pulsatility during the follicular phase. However, our results
are in contradiction to those of Studd and Panay [9], who
reported data from 28 premenopausal women with CFS.
Of these, 25% showed low plasma estradiol concen-
trations. Those authors reported that CFS may represent a
hypoestrogenic state and recommended the use of
hormone replacement therapy for women with CFS. In
addition, they claimed that 80% of patients improved after




Baseline characteristics of patients and healthy control subjects
Patients Controls
Fibromyalgia Chronic fatigue syndrome
Variable (N = 68) (N = 62) (N = 46)
Age (years) 31.43 ± 7.81  32.55 ± 6.61 31.54 ± 6.86
Disease duration (years) 3.96 ± 4.23 4.28 ± 4.12 –
FIQ score 59.23 ± 10.28 – 12.83 ± 7.21
Pain intensity (VAS) 5.03 ± 1.18 4.49 ± 1.83 0.47 ± 0.880
Tender point count 13.18 ± 1.79 6.49 ± 3.51 3.49 ± 2.81
Symptoms experienced [No. (%)]
Morning stiffness 42 (62) 24 (39) 3 (7)
Muscle spasm 39 (57) 15 (24) 2 (4)
Fatigue 48 (71) 62 (100) 4 (9)
Skinfold tenderness 56 (82) 29 (47) 2 (4)
Sleep disturbance 54 (79) 27 (44) 2 (4)
Cigarette smoking 31 (46) 30 (48) 26 (57)
Menstrual cycle
Age at menarche 12.91 ± 0.28 13.02 ± 0.25 13.14 ± 0.21
Cycle length (days) 13.14 ± 0.21 28.87 ± 0.19 29.07 ± 0.27
Days of menstrual flow 4.82 ± 0.36 4.97 ± 0.28 4.89 ± 0.32
Marital status [No. (%)]
Married 45 (66) 39 (63) 28 (61)
Single 13 (20) 14 (23 10 (23)
Divorced 7 (12) 6 (10) 4 (9)
Other 3 (2) 3 (4) 3 (7)
Highest educational level achieved [No. (%)]
Elementary school 31 (46) 30 (48) 20 (44)
Secondary school 15 (22) 13 (21) 13 (28)
University/High school 22 (32) 19 (31) 13 (28)
Employment status [No. (%)]
Unemployed 5 (7) 5 (8) 3 (7)
Employed 7 (10) 5 (8) 7 (15)
Retired 3 (4) 4 (6) 2 (4)
Homemaker 39 (58) 37 (60) 24 (52)
Student 11 (16) 8 (13) 7 (15)
Others 3 (5) 3 (5) 3 (7)
Values are means ± standard deviation, except where indicated as number and percentage of the group. FIQ, Fibromyalgia Impact Questionnaire;
VAS: Visual Analog Scale; –, not applicable.gens. A similar suggestion as to the effect of HRT has
been made for women with fibromyalgia by Waxman and
Zatskis [10]. The authors reported estrogen deficit as a
prominent promoting factor in the majority of patients with
fibromyalgia and recommended estrogen therapy for
treatment of fibromyalgia. Further clinical and experimental
studies are required to determine the role of sex hormones
in the pathogenesis of this condition.
In our study, morning cortisol levels were lower in women
with CFS than in healthy controls. Some studies of the
HPA axis in CFS show a mild hypocortisolism of central
origin, in contrast to hypercortisolism of major depression
[21,22]. In an early study of the HPA axis in patients with
CFS, Demitract and colleagues [6] reported low 24-hour
urine free cortisol compared with that of control subjects.
Baseline evening plasma corticotropin levels were
elevated and cortisol levels were depressed. Significantly
lower baseline cortisol levels were reported in an earlier
study [23]. However, most further studies have failed to
replicate those findings. Differences in methodology, and
sample characteristics, may explain the variety of results.
Previous studies suggested the existence of perturbation
of the HPA axis in fibromyalgia [24,25], and a hyper-
reactive response of adrenocorticotrophic hormone and
GH to various stimuli was detected, whereas in the
cortisol response, a decrease occurred [26–28]. Crofford
[26] reported elevated serum levels of 24-hour free
cortisol, resulting in a loss of normal diurnal cortisol
Arthritis Research & Therapy    Vol 6 No 3 Gur et al.
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Table 2
Serum hormones and scores on the Beck Depression Inventory (BDI) in patients and healthy control subjects
Patients Controls
Fibromyalgia Chronic fatigue syndrome
Variable (N = 68) (N = 62) (N = 46)
BDI score 22.48 ± 12.53* 24.18 ± 12.67* 12.48 ± 5.83
LH 7.65 ± 6.45 6.63 ± 5.89 6.88 ± 4.69
FSH 5.92 ± 4.38 6.41 ± 4.35 6.69 ± 4.87
Progesterone 4.13 ± 5.76 3.69 ± 4.18 3.78 ± 3.97
Estradiol 113.24 ± 89.48 105.52 ± 101.12 94.15 ± 59.34
Prolactin 23.34 ± 17.12 24.19 ± 16.88 19.35 ± 10.45
Cortisol 10.14 ± 6.49* 10.38 ± 5.82* 13.52 ± 6.25
Values are means ± standard deviation. *Significantly different from control value (P < 0.05). FSH, follicle-stimulating hormone; LH, luteinizing
hormone.
Table 3
Serum hormones in patients and control group according to score on the Beck Depression Inventory (BDI)a
Patients with fibromyalgia Patients with CFS Healthy controls
BDI < 17 BDI ≥ 17 BDI < 17 BDI ≥ 17
(N = 32) (N = 36) (N = 21) (N = 41) (N = 46)
Age (years) 31.86 ± 7.29 30.65 ± 7.65 31.98 ± 6.57 32.76 ± 7.18 31.54 ± 6.86
LH 11.65 ± 10.42* & # 6.43 ± 4.28 6.21 ± 7.26 6.71 ± 5.87 6.88 ± 4.69
FSH 7.13 ± 3.21 6.25 ± 2.84 5.87 ± 3.69 6.81 ± 4.43 6.69 ± 4.87
Progesterone 4.19 ± 4.56 4.73 ± 5.56 4.18 ± 4.65 3.72 ± 5.27 3.78 ± 3.97
Estradiol 113.48 ± 69.45 121.42 ± 90.26 98.39 ± 87.11 107.23 ± 91.57 94.15 ± 59.34
Prolactin 26.08 ± 32.19 21.03 ± 11.32 23.41 ± 28.49 20.87 ± 27.36 19.35 ± 10.45
Cortisol 11.94 ± 6.56# 10.11 ± 5.67* 8.96 ± 4.28* 10.52 ± 5.45* 13.52 ± 6.25
Values are means ± standard deviation. aA BDI score of ≥17 was considered to indicate depression. *Significantly different from control (P < 0.05);
&significantly different from fibromyalgia group with BDI ≥ 17 (P < 0.05); #significantly different from CFS group with BDI < 17 (P < 0.05). CFS,
chronic fatigue syndrome; FSH, follicle-stimulating hormone; LH, luteinizing hormone.fluctuation, and with stimulation a brisk but lesser increase
in cortisol level in fibromyalgia. An earlier study by Griep and
colleagues [24] had found that neither basal levels nor
stimulated levels of cortisol differed between groups. In a
later study by the same group, mild hypocortisolemia was
observed [29]. Again, differences in methodology, and
sample characteristics, may explain the differences in results.
It is known that most patients with fibromyalgia and CFS
also have depressive symptoms, and depressive patients
suffering from pain are not uncommon. Some investigators
have therefore suggested a possible connection between
fibromyalgia, CFS, and depression. The first pointer to
such a connection is that most patients with fibromyalgia
and CFS exhibit depressive symptoms such as fatigue,
sleep disturbances, and anxiety [30]. Second, phenomeno-
logical similarities exist between chronic pain syndrome —
which has been claimed to be related to depression — and
fibromyalgia [31]. Finally, an increased prevalence of
depression has been found in patients with fibromyalgia,
and bipolar illness has been diagnosed more frequently in
close relatives of such patients [32]. Similarities in
patients with fibromyalgia and depression [33] raise the
possibility of a neuroendocrine relationship between these
two disorders. It is unclear whether the depression
develops as a reaction to the chronic pain or represents
an independent disease within the fibromyalgia [34].
In our study, high BDI scores (≥17) were detected in 53%
and 66%, respectively, of patients with fibromyalgia and
CFS. When compared according to score for depressive
symptoms, cortisol levels were significantly lower in
fibromyalgia patients with high BDI scores than in
controls, but not in those with low BDI scores. Cortisol
levels in CFS patients with and those without depressive
symptoms were significantly lower than in controls,
whereas there was no significant difference between
fibromyalgia patients with and those without depressive
symptoms. In patients without depressive symptoms,
cortisol levels were lower in CFS than in fibromyalgia.
Comorbid depressive illness is one important confounder
present in approximately 50% of CFS patients [35]. High
circulating cortisol is a well-replicated finding in major
depression [36], and so presence of depression makes
the cortisol findings more difficult to interpret. Of the 10
subjects studied by Wood and colleagues [37], 5 had
high BDI scores. This may explain their finding of
significantly raised baseline cortisol in their sample of CFS
patients. Scott and Dinan [22] reported a finding of low
urine free cortisol in patients with CFS compared with
healthy controls. In addition, there was no difference in
this constituent between depressed and nondepressed
patients with CFS. In another study [38], the same group
reported blunted corticotropin and cortisol in response to
administration of ovine corticotropin-releasing hormone,
without differences in basal levels.
In our study we found that the morning cortisol levels in
the fibromyalgia patients with high BDI scores were
significantly lower than those with low BDI scores. This is
in contradiction to the hypercortisolism of classical major
depression. In recent years, however, it has become
increasingly apparent that depression is a heterogeneous
condition, from both a psychological and a physiological
perspective [39]. Moreover, decreased activity of the HPA
axis was reported in some stress-related states such as
CFS and atypical and seasonal depression [40]. Forms of
depressive illness dominated by reduced energy, a
reactive mood, and a reversal of the typical pattern of
vegetative features seen in classical depression have
been described [39]. There may be overlap between
symptoms of fibromyalgia and those depressive subtypes
or reactive forms of depression in fibromyalgia. This
condition may explain the low cortisol levels in patients
with fibromyalgia in this study. It may also explain both low
morning cortisol in patients with CFS and the lack of
abnormalities of hormones of the HPG axis in this study.
This is the first study comparing levels both of hormones
of the HPG axis and of cortisol, which is the most
important hormone of the HPA axis, in follicular-phase
women with fibromyalgia and CFS and evaluating relations
between scores for depressive symptoms and the HPG
and HPA axes in these patients. Thus, comparison of CFS
with fibromyalgia highlights both similarities and
differences in neuroendocrinology. It may be that the
differences reflect distinct pathophysiologies for the two
syndromes. However, the similarities, both in reduced
HPA activation, symptomatology, and abrupt stress-
related onset, suggest otherwise.
Cortisol levels peak in early morning and need to be
collected before patients rise in the morning; and
determining single levels of hormones that are secreted in
a pulsatile fashion may not be representative of normal
functioning. But one should keep in mind that basal
hormone levels alone do not reflect activity of the HPA and
HPG axes. Sometimes only dynamic (stimulation) tests
find differences in the activity of HPA and HPG axes in
fibromyalgia. We did not carry out early-morning and
repeated measures of these hormones because of the
large number of subjects in our study. This point is a
limitation of our study.
Conclusion
Our study in follicular-phase women with fibromyalgia and
CFS suggests that in these patients, despite low morning
cortisol concentrations, the only abnormality in hormones
of the HPG axis is high LH levels in fibromyalgia patients
with low BDI scores. The score for depressive symptoms
may have some relation to cortisol and LH levels, or low
cortisol levels may be a biological factor that contributes
to depressive symptoms in fibromyalgia. These parameters
Available online http://arthritis-research.com/content/6/3/R232
R237therefore must be taken into account in future
investigations. These results suggest that hormones of
both the HPA and the HPG axis should be evaluated for
an understanding of the pathophysiology of fibromyalgia
and CFS and when considering approaches to treatment.
Larger clinical studies and follow-up surveys are needed




1. Wolfe F, Ross K, Anderson J, Russell IJ, Herbert L: The preva-
lence and characteristics of fibromyalgia in the general popu-
lation. Arthritis Rheum 1995, 38:19-28.
2. Gunn WJ, Connell DB, Randall B: Epidemiology of chronic
fatigue syndrome: the Centers for Disease Control Study. In
Chronic Fatigue Syndrome. Edited by Bock GR, Whelan J. Chich-
ester: John Wiley & Sons; 1993:83-101.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C,
Goldenberg DL, Tugwell P, Campbell SM, Abeles  M, Clark P:
The American College of Rheumatology 1990 Criteria for the
classification of fibromyalgia. Report of the Multicenter Crite-
ria Committee. Arthritis Rheum 1990, 33:160-172.
4. Crofford LJ, Engleberg NC, Demitrack MA: Neurohormonal per-
turbations in fibromyalgia. Baillière’s Clin Rheumatol 1996, 10:
365-578.
5. Korszun A, Young A E, Engleberg NC, Masterson L, Dawson EC,
Spindler K, Crofford LJ: Follicular phase hypothalamic-pitu-
itary-gonadal axis function in women with fibromiyalgia and
chronic fatigue syndrome. J Rheumatol 2000, 27:1526-1530.
6. Demitrack MA, Dale JK, Straus SE, Laue L, Listwak SJ, Kruesi MJ,
Chrousos GP, Gold PW: Evidence for impaired activation of the
hypothalamic-pituitary-adrenal axis in patients with chronic
fatigue syndrome. J Clin End Metab 1991, 73:1224-1234.
7. Neeck G: Pathogenic mechanism of fibromyalgia. Ageing
Research Rev 2002, 1:243-255.
8. Neeck G, Crofford LJ: Neuroendocrine perturbations in
fibromyalgia and chronic fatigure syndrome. Rheumatic
Disease Clinics of North America 2000, 26:989-1002.
9. Studd J, Panay N: Chronic fatigue syndrome [letter]. Lancet
1996, 348:1384.
10. Waxman J, Zatskis SM: Fibromyalgia and menopause. Exami-
nation of the relationship. Postgrad Med J 1986, 80:165-167.
11. Xiao E, Luckhaus J, Niemann W, Ferin M: Acute inhibition of
gonadotropin secretion by corticotrophin-releasing hormone
in the primate: are the adrenal glands involved? Endocrinology
1989:124:1632-1637.
12. Riedel W, Layka H, Neeck G: Secretory pattern of GH, TSH,
thyroid hormones, ACTH, cortisol, FSH, and LH in patients
with fibromyalgia syndrome following systemic injection of
the relevant hypothalamic-releasing hormones. Z Rheumatol
1998, 57:81-87.
13. Korszun A, Sackett-Lundeen L, Papadopoulos E, Brucksch C,
Masterson L, Engelberg NC, Haus E, Demitrack MA, Crofford L:
Melatonin levels in women with fibromyalgia and chronic
fatigue syndrome. J Rheumatol 1999, 26:2675-2680.
14. Akkus S, Delibas N, Tamer MN: Do sex hormones play a role in
fibromyalgia? Rheumatology 2000, 39:1161-1163.
15. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C,
Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P: The
American College of Rheumatology 1990 Criteria for the Clas-
sification of Fibromyalgia. Report of the Multicenter Criteria
Committee. Arthritis Rheum 1990, 33:160-72.
16. Fukuda K, Straus S, Hickie I, Sharpe MC, Dobbins JG, Komaroff
A: The chronic fatigue syndrome: a comprehensive approach
to its definition and study. Ann Intern Med 1994, 121:953-959.
17. American Psychiatric Association. Diagnostic and Statistical
Manual of Mental Disorders. 4th edition. Washington, DC: US
Government Printing Office; 1995.
18. Gur A, Karakoc M, Nas K, Cevik R, Sarac J: Cytokines and
depression in cases with fibromyalgia. J Rheumatol 2002, 29:
358-361.
19. Heim C, Ehlert U, Dirk H, Helhammer H: The potential role of
hypocortisolism in the pathophysiology of stress-related
bodily disorders. Psychoneuroendocrinology 2000, 25:1-35.
20. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM:
Hypothalamic-pituitary–insulin-like growth factor-I axis dys-
function is patients with fibromyalgia. J Rheumatol 1997,
24:1384-1389.
21. Cleare AJ, Bearn J, Allain T, McGregor A, Wesseley S, Murray
RM, O’Keane V: Contrasting neuroendocrine responses in
depression and chronic fatigue syndrome. J Affective Disord
1995, 35:283-289.
22. Scott LV, Dinan TG: Urinary free cortisol excretion in chronic
fatigue syndrome, major depression, and in healthy volun-
teers. J Affect Disord 1998, 47:49-54.
23. Poteliakhoff A: Adrenocortical activity and some clinical find-
ings in chronic fatigue. J Psychosom Res 1981, 25:91-95.
24. Mc Gain GA, Tilbe KS: Diurnal hormone variation in fibromyal-
gia syndrome: a comparison with rheumatoid arthritis. J
Rheumatol 1989, 19:154-157.
25. Ferraccioli G, Cavalieri F, Salaffi F, Fontana S, Scita F, Nolli M,
Maestri D: Neuroendocrinologic findings in primary fibromyalgia
and in other chronic rheumatic conditions (rheumatoid arthritis,
low back pain) [editorial]. J Rheumatol 1990, 17:869-873.
26. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D,
Kling MA, Sternberg EM, Gold PW, Chrousos GP, Wilder RL:
Hypothalamic-pituitary-adrenal axis perturbations in patients
with fibromyalgia. Arthritis Rheum 1994, 11:1583-1592.
27. Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the
hypothalamic-pituitary-adrenal axis in the primary fibromyal-
gia syndrome. J Rheumatol 1993, 20:469-474.
28. Griep EN, Boersma JW, de Kloet ER: Pituitary release of growth
hormone and prolactin in the primary fibromyalgia syndrome.
J Rheumatol 1994, 21:2125-2130.
29. Griep EN, Boersma JW, Lentes EG, Prins AP, van der Korst JK,
de Kloet ER: Function of the hypothalamic-pituitary-adrenal
axis in patients with fibromyalgia and low back pain. J
Rheumatol 1998, 25:1375-1381.
30. Schaffer CB, Donlon PT, Bittle RM: Chronic pain and depres-
sion: A clinical and family history survey. Am J Psychiatry
1980, 137:118-120.
31. Blumer D, Zorick F, Heilbronn M, Roth T: Biological markers for
depression in chronic pain. J Nerv Ment Dis 1982, 170:425-
428.
32. Thase ME: Mood disorders: neurobiology. In  Comprehensive
Textbook of Psychiatry. 7th edition. Edited by Sadock BJ, Sadock
VA. Philadelphia: Lippincott; 2000:1318-1328.
33. Yunus MB, Ahles TA, Aldag JC, Masi AT: Relationship of clinical
features with psychological status in primary fibromyalgia.
Arthritis Rheum 1991, 34:15-21.
34. Neeck G: Neuroendocrine and hormonal perturbations and
relations to the serotonergic system in fibromyalgia patients.
Scand J Rheumatol 2000, 29:8-12.
35. Parker AJ, Wessely S, Cleare AJ: The neuroendocrinology of
chronic fatigure syndrome and fibromyalgia. Psychol Med
2001, 31:1331-1345.
36. Dinan TG: Glucocorticoids and the genesis of depressive
illness. A psychobiological model. Br J Psychiatry 1994, 164:
365-371.
37. Wood B , Wessely S, Papadopoulos A, Poon L, Checkley S: Sali-
vary cortisol profiles in chronic fatigure sydrome. Neuropsy-
chobiology 1998, 37:1-4.
38. Scott LV, Medback S, Dinan G: Blunted adrenocrticotropin and
cortisol responses to corticotropin-releasing hormone stimu-
lation in chronic fatigue syndrome. Acta Psychiatr Scand 1998,
97:450-457.
39. Crofford LJ: The hypothalamic-pituitary-adrenal stress axis in
fibromyalgia and chronic fatigue syndrome [review]. Z
Rheumatol 1998, 57:67-71.
40. Tsigos C, Chrousos GP: Hypothalamic-pituitary-adrenal axis,
neuroendocrine factors and stress. J Psychosom Res 2002,
53:865-871.
Correspondence
Ali Gur, MD, Physical Medicine and Rehabilitation, Dicle University
School of Medicine, 21280 DiyarbakIr, Turkey. Tel: +90 412 2488001;
fax: +90 412 2488579; e- mail: alig@dicle.edu.tr
Arthritis Research & Therapy    Vol 6 No 3 Gur et al.
R238